Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa [clinicaltrials:NCT00866619]

Bio2RDF identifier

NCT00866619

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00866619

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00866619

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

15,459

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00866619 arm group 22145818c5d1fa5155378cb154d6a9e9 [clinicaltrials_resource:NCT00866619/arm-group/22145818c5d1fa5155378cb154d6a9e9]

NCT00866619 arm group 54fd7f331114ebca6b1521d43f284a24 [clinicaltrials_resource:NCT00866619/arm-group/54fd7f331114ebca6b1521d43f284a24]

NCT00866619 arm group 8c469a60cd125f5e79edb6e92ac5f8bd [clinicaltrials_resource:NCT00866619/arm-group/8c469a60cd125f5e79edb6e92ac5f8bd]

NCT00866619 arm group c82e7c43426c06fefdd91118da629fa2 [clinicaltrials_resource:NCT00866619/arm-group/c82e7c43426c06fefdd91118da629fa2]

NCT00866619 arm group cf510e55f33e047cbe0895dd07d96b1c [clinicaltrials_resource:NCT00866619/arm-group/cf510e55f33e047cbe0895dd07d96b1c]

NCT00866619 arm group fe4aa76e1aa7c6f3707dd4a19b342f04 [clinicaltrials_resource:NCT00866619/arm-group/fe4aa76e1aa7c6f3707dd4a19b342f04]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:6d3272648fa3196a9f795ea530fba3c5

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this obs ...... cine in infants and children.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy of GSK Biologicals' C ...... Infants and Children in Africa

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:60f23a1d59bbc8cfd68028ed881d6224]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:94bf5fb45a0a3eb95e0ed7cd8c73dbac]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:031a01844b7fab409255855c99509969]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:0711d49fe3e03ee59713e77cad9d9ec8]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:077cc06b5f958c7cd5df1e636f547614]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:0c3c1d5cd85c1b8bbcd4a00da3744cc2]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:0ce4473a278b095b659b2b6ad6711e3f]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:0e2b036bb0d8daec740b25d81fa1009e]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:122347321110b521101be5363dba124b]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:128b8593239e899d60bacf9798aee1aa]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:172a0fd7f8db1a4cc1599080233d1fb0]

For a primary schedule, the occurrence of cases of malaria meeting the primary case definition for clinical malaria disease. Starting 14 days post Dose 3 for 12 months in children aged 6-12 weeks at the time of Dose 1, or until the time at which 450 subjects experience a case, whichever occurs later. [clinicaltrials_resource:27de7856895d26d3abcf5951cc0b61ce]

collaborator [clinicaltrials_vocabulary:collaborator]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

completion date [clinicaltrials_vocabulary:completion-date]

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

The protocol posting do ...... hase were conducted together.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00866619 [clinicaltrials_resource:9c613d7c94f1c188b24707c7a052df69]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2009-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Polio Sabin Oral Polio Vaccine (GSK) [clinicaltrials_resource:1e22c6c2ff974224934cee7e2bf56158]

TritanrixHepB/Hib [clinicaltrials_resource:3d541d50d8852a12a1a54576f496af59]

Meningococcal C Conjugate Vaccine [clinicaltrials_resource:56684cdf0ff5d68060701a01e0a046b8]

Malaria Vaccine 257049 [clinicaltrials_resource:b4190186b59fff55bc5132182dc6f6bb]

Cell-culture rabies vaccine [clinicaltrials_resource:cbb917911032224c9fce59c1797b8ae6]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

GSK Investigational Site [clinicaltrials_resource:5ab3993faa901a0eaea318d143c5194f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00866619

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

6

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Efficacy of GSK Biologicals' C ...... Infants and Children in Africa

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

110,021

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Kenya: KEMRI (Kenya Medical Research Institute) [clinicaltrials_resource:a6e385d49d6002d72ff7543c48b35efc]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00866619 study design [clinicaltrials_resource:a24f10d14d500115ffc4cef0667ced6d]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00866619

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00866619

http://www.w3.org/2001/XMLSchema#string

title

Efficacy of GSK Biologicals' C ...... Infants and Children in Africa

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy of GSK Biologicals' C ...... a [clinicaltrials:NCT00866619]

@en